Genomic Cancer Testing Market is Estimated To Witness High Growth Owing To Technological Advancements and Increasing Incidence of Cancer
The Genomic Cancer Testing Market is estimated to be valued at US$16.15 billion in 2023 and is expected to exhibit a CAGR of 16.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Genomic cancer testing involves analyzing the DNA or RNA of a cancer cell to identify genetic abnormalities and provide insights into the disease condition of patients. This information helps clinicians in developing personalized treatment plans and improving patient outcomes. Genomic cancer testing finds applications in various cancer types, including breast cancer, lung cancer, prostate cancer, and colorectal cancer, among others.
Market Dynamics:
The growing prevalence of cancer worldwide is one of the primary drivers propelling the growth of the genomic cancer testing market. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths in 2018.
Furthermore, technological advancements in genomic sequencing technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), are driving market growth. These advancements have improved the accuracy, efficiency, and scalability of genomic testing, leading to increased adoption.
Segment Analysis:
The genomic cancer testing market can be segmented based on cancer type, technology, end-user, and region. By cancer type, the dominating segment is expected to be lung cancer, due to the high prevalence of lung cancer worldwide. Genomic testing plays a crucial role in determining the genetic makeup of lung cancer tumors, aiding in the selection of appropriate treatment options. Moreover, advancements in targeted therapies for lung cancer, such as immunotherapy and personalized medicine, further contribute to the dominance of this segment in the market.
PEST Analysis:
Political: The genomic cancer testing market is influenced by government regulations regarding the approval and reimbursement of genomic tests. Policies and guidelines related to data privacy and protection also impact market growth.
Economic: The increasing healthcare expenditure, growing prevalence of cancer, and rising demand for precision medicine are key economic factors driving the genomic cancer testing market.
Social: The growing awareness among individuals about the benefits of early cancer diagnosis and personalized treatment options is driving the demand for genomic cancer testing. The shift towards proactive healthcare management is also contributing to market growth.
Technological: Advances in genomic sequencing technologies, such as next-generation sequencing (NGS), have revolutionized the field of cancer testing. The development of liquid biopsy techniques and the integration of artificial intelligence in genomic data analysis have also enhanced the efficiency and accuracy of genomic cancer testing.
Key Takeaways:
The Global Genomic Cancer Testing Market Size is expected to witness high growth, exhibiting a CAGR of 16.1% over the forecast period. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for personalized treatments. The lung cancer segment is expected to dominate the market due to the high prevalence of lung cancer worldwide and the advancements in targeted therapies for this cancer type.
In terms of regional analysis, North America is anticipated to be the fastest-growing and dominating region in the genomic cancer testing market. The presence of well-established healthcare infrastructure, favorable reimbursement policies, and high adoption of advanced genomic technologies contribute to this growth in North America.
Key players operating in the genomic cancer testing market include Illumina, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc. (Roche), Invitae Corporation, NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc. (Exact Sciences Corporation), Caris Life Sciences, ArcherDX, Inc. (Invitae Corporation), Guardant Health, Inc., Personal Genome Diagnostics Inc., Biocept, Inc., and Tempus Labs, Inc. These key players are focused on strategic collaborations, product launches, and technological advancements to maintain their market position.